Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

452 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib.
Satouchi M, Negoro S, Funada Y, Urata Y, Shimada T, Yoshimura S, Kotani Y, Sakuma T, Watanabe H, Adachi S, Takada Y, Yatabe Y, Mitsudomi T. Satouchi M, et al. Among authors: urata y. Br J Cancer. 2007 Apr 23;96(8):1191-6. doi: 10.1038/sj.bjc.6603710. Epub 2007 Mar 27. Br J Cancer. 2007. PMID: 17387341 Free PMC article.
Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer.
Urata Y, Okamoto I, Takeda M, Hattori Y, Okuno K, Shimada T, Kurata T, Kaneda H, Miyazaki M, Terashima M, Tanaka K, Morita S, Nakagawa K, Negoro S, Satouchi M. Urata Y, et al. Cancer. 2013 Jun 15;119(12):2275-81. doi: 10.1002/cncr.28048. Epub 2013 Apr 4. Cancer. 2013. PMID: 23558513 Free article. Clinical Trial.
A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001).
Hattori Y, Satouchi M, Katakami N, Fujita S, Kaji R, Hata A, Urata Y, Shimada T, Uchida J, Tomii K, Morita S, Negoro S. Hattori Y, et al. Among authors: urata y. Cancer Chemother Pharmacol. 2014 Jan;73(1):17-23. doi: 10.1007/s00280-013-2290-y. Epub 2013 Oct 20. Cancer Chemother Pharmacol. 2014. PMID: 24141372 Clinical Trial.
A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
Hattori Y, Satouchi M, Shimada T, Urata Y, Yoneda T, Mori M, Nishimura T, Sunadome H, Kumagai T, Imamura F, Fujita S, Kaji R, Hata A, Tachihara M, Morita S, Negoro S. Hattori Y, et al. Among authors: urata y. Lung Cancer. 2015 Feb;87(2):136-40. doi: 10.1016/j.lungcan.2014.12.007. Epub 2014 Dec 19. Lung Cancer. 2015. PMID: 25553650 Clinical Trial.
A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002).
Hata A, Katakami N, Fujita S, Nanjo S, Takeshita J, Tanaka K, Kaneda T, Nishiyama A, Nishimura T, Nakagawa A, Otsuka K, Morita S, Urata Y, Negoro S. Hata A, et al. Among authors: urata y. Cancer Chemother Pharmacol. 2015 Jun;75(6):1267-72. doi: 10.1007/s00280-015-2755-2. Epub 2015 Apr 30. Cancer Chemother Pharmacol. 2015. PMID: 25925001 Clinical Trial.
A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
Nishino K, Imamura F, Kumagai T, Katakami N, Hata A, Okuda C, Urata Y, Hattori Y, Tachihara M, Yokota S, Nishimura T, Kaneda T, Satouchi M, Morita S, Negoro S. Nishino K, et al. Among authors: urata y. Lung Cancer. 2015 Aug;89(2):146-53. doi: 10.1016/j.lungcan.2015.05.022. Epub 2015 Jun 6. Lung Cancer. 2015. PMID: 26093793 Clinical Trial.
452 results